Description: Milademetan tosylate (formerly DS3032b; DS3032; DS-3032b; DS-3032), the tosylate salt of Milademetan, is a selective and orally bioavailable inhibitor of MDM2-p53 protein protein interaction with potential anticancer activity.
References:
[1]. ARYL SULFONOHYDRAZIDES. WO 2017069289 A1.
[2]. Milademetan, an oral MDM2 inhibitor, in well-differentiated/dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas. European Journal of Cancer 138S2 (2020) S1–S62.
[3]. Development of novel PROTAC Small-Molecule Degraders of MDM2 Protein and Peptidomimetic Inhibitors Targeting WDR5-MLL1 Protein-Protein Interaction.
[4]. Viktor Arnhold, et al. Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma. Oncotarget. 2018 Jan 5; 9(2): 2304–2319.
[5]. Predictive gene signatures determine tumor sensitivity to MDM2 inhibition. Cancer Res. 2018 Feb 28. pii: canres.0949.2017. doi: 10.1158/0008-5472.
Related CAS #: 1398568-47-2 (free base) 2095625-97-9 (tosylate hydrate) 1398569-75-9 (tosylate)